EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease



Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease



Saudi Journal of Kidney Diseases and Transplantation 27(6): 1182-1187



NlmCategory="UNASSIGNED">The anemia of chronic kidney disease (CKD) is a common comorbidity seen in kidney diseases. It is also associated with increased cardiovascular morbidity and mortality and diminished quality of life. Often, patients with CKD of different stages require erythropoiesis-stimulating agents (ESAs) to maintain their hemoglobin (Hb) within the target range. Darbepoetin alfa is a newer ESA with a longer half-life than recombinant human erythropoietin (EPO). The objective of this study is to assess the efficacy and safety profile of twice-monthly (Q2W) and once a month (1QM) darbepoetin alfa in CKD patients, not on dialysis. The secondary objective was to assess the appropriate dose conversion from EPO to darbepoetin. Patients with CKD not on dialysis, receiving darbepoetin alfa every other week, or once every month, and with stable Hb levels between 10 and 12 g/dL, were enrolled in this single-center, open-label, single-arm study. In this study, 36 patients (21 female, 15 male) were enrolled with a mean age of 46.4 ± 20.12 years. About 56% of the patients (n = 20) received darbepoetin alfa 40 μg Q2W for more than three months and 36% (n = 13) were on once-monthly doses, whereas the other 8% (n = 3) were on variable doses ranging from 20 to 60 μg every two weeks. More than 80% of the patients were converted from short-acting EPO to darbepoetin corresponding to a conversion ratio of 672.2 IU:1 μg (standard deviation = 488.5). Hb levels ≥10 g/dL were maintained in 77.78% of the patients. The safety profile of darbepoetin alfa in this study was recorded, and no significant adverse effects were noted. Our study suggests that darbepoetin alfa, administered in fixed small doses and frequency of Q2W or Q1M, maintained Hb levels ≥10 g/dL in patients with CKD, not on dialysis.

(PDF emailed within 1 workday: $29.90)

Accession: 058122706

Download citation: RISBibTeXText

PMID: 27900963



Related references

Management of anemia in chronic kidney disease patients using a darbepoetin treatment algorithm A twelve month experience. Journal of the American Society of Nephrology 14(Abstracts Issue): 782A, November, 2003

Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Pharmacotherapy 22(9 Part 2): 141S-149S, September, 2002

Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. European Journal of Clinical Pharmacology 65(2): 169-178, 2008

Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology 21(8): 1144-1152, 2006

Evaluation of anemia management by algorithms in patients with chronic kidney disease who are not receiving dialysis. Canadian Journal of Hospital Pharmacy 64(2): 141-146, 2012

Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Nephrology, Dialysis, Transplantation 25(7): 2237-2244, 2010

Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrology, Dialysis, Transplantation 18(3): 576-581, 2003

Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis. Nephrology 19(5): 266-274, 2014

Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Current Medical Research and Opinion 22(10): 2023-2030, 2006

Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa. PharmacoTherapy 22(9 Pt 2): 129s-132s, 2002

Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease. Polski Merkuriusz Lekarski 28(163): 13-17, 2010

Darbepoetin alfa administered once every 4 weeks maintains Hb levels in patients with chronic kidney disease receiving dialysis. Nephrology Dialysis Transplantation 17(Abstracts Supplement 1): 136, 2002

Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purification 30(3): 186-194, 2011

Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. Journal of Clinical Pharmacology 50(9 Suppl): 75s-90s, 2011

Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data. Nephrology Nursing Journal 32(4): 399-407, 2005